Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.8
2.7
Journals
Brain Sciences
Special Issues
Diagnosis and Treatment of Multiple Sclerosis: Past, Present, Future
share announcement

Diagnosis and Treatment of Multiple Sclerosis: Past, Present, Future

A special issue of Brain Sciences (ISSN 2076-3425).

Deadline for manuscript submissions: closed (15 March 2019) | Viewed by 4696

Special Issue Editor

Dr. Evanthia Bernitsas

E-Mail Website
Guest Editor
Multiple Sclerosis Center, Wayne State University School of Medicine, Detroit, MI 48201, USA
Interests: neuroimmunology; cognition; fatigue; neuroimaging
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Multiple Sclerosis is an autoimmune, multifaceted, chronic and progressive disease with a complex etiology and pathophysiology. As it affects people during the most productive years of their lives, prompt diagnosis and effective treatment is of paramount importance. Over the last decade, tremendous progress has been made. Novel technology, including advanced imaging modalities, led to earlier diagnosis and development of new disease modifying therapies. However, many questions are still unanswered. At this point, MS is still a treatable, but non-curable disease.

In this Special Issue, we invite you to submit manuscripts addressing past, present and future diagnostic approaches, the development of new biomarkers, established and emerging therapeutic targets, neuroprotective and remyelinating therapies. Critical reviews of clinical trials, articles focusing on multidisciplinary interventions and personalized approaches and manuscripts discussing future prospects for the MS patients are welcome. Submissions addressing the role of nutrition, supplements, life style modifications and exercise are encouraged.

Dr. Evanthia Bernitsas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Multiple Sclerosis (MS)
  • progressive disease
  • biomarkers
  • neuroprotective and remyelinating therapies
  • nutrition
  • life style
  • exercise

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 3333 KiB  
Article
Design of Linear and Cyclic Mutant Analogues of Dirucotide Peptide (MBP82–98) against Multiple Sclerosis: Conformational and Binding Studies to MHC Class II
by George Deraos, Eftichia Kritsi, Minos-Timotheos Matsoukas, Konstantina Christopoulou, Hubert Kalbacher, Panagiotis Zoumpoulakis, Vasso Apostolopoulos and John Matsoukas
Brain Sci. 2018, 8(12), 213; https://doi.org/10.3390/brainsci8120213 - 4 Dec 2018
Cited by 7 | Viewed by 3991
Abstract
Background: Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system. MS is a T cell-mediated disease characterized by the proliferation, infiltration, and attack of the myelin sheath by immune cells. Previous studies have shown that cyclization provides molecules with strict [...] Read more.
Background: Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system. MS is a T cell-mediated disease characterized by the proliferation, infiltration, and attack of the myelin sheath by immune cells. Previous studies have shown that cyclization provides molecules with strict conformation that could modulate the immune system. Methods: In this study, we synthesized peptide analogues derived from the myelin basic protein (MBP)82–98 encephalitogenic sequence (dirucotide), the linear altered peptide ligand MBP82–98 (Ala91), and their cyclic counterparts. Results: The synthesized peptides were evaluated for their binding to human leukocyte antigen (HLA)-DR2 and HLA-DR4 alleles, with cyclic MBP82–98 being a strong binder with the HLA-DR2 allele and having lower affinity binding to the HLA-DR4 allele. In a further step, conformational analyses were performed using NMR spectroscopy in solution to describe the conformational space occupied by the functional amino acids of both linear and cyclic peptide analogues. This structural data, in combination with crystallographic data, were used to study the molecular basis of their interaction with HLA-DR2 and HLA-DR4 alleles. Conclusion: The cyclic and APL analogues of dirucotide are promising leads that should be further evaluated for their ability to alter T cell responses for therapeutic benefit against MS. Full article
(This article belongs to the Special Issue Diagnosis and Treatment of Multiple Sclerosis: Past, Present, Future)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop